Tian Dai

Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study

Sant P. Chawla, Jean‐Yves Blay, Piotr Rutkowski et al. · The Lancet Oncology · 2019 · 244 citations

Bone Disease, Medicine, Pathology +7

Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial

Robert E. Coleman, Dianne M. Finkelstein, Carlos H. Barrios et al. · The Lancet Oncology · 2019 · 244 citations · Full text

Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML).

Farhad Ravandi, Roland B. Walter, Marion Subklewe et al. · Journal of Clinical Oncology · 2020 · 104 citations

Mixed-phenotype Acute Leukemia, Immunology, Pharmacotherapy +18

Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Marion Subklewe, Anthony S. Stein, Roland B. Walter et al. · Blood · 2019 · 86 citations

Therapeutic Plasma Exchange in Children With Thrombocytopenia-Associated Multiple Organ Failure: The Thrombocytopenia-Associated Multiple Organ Failure Network Prospective Experience

James D. Fortenberry, Trung C. Nguyen, Jocelyn R. Grunwell et al. · Critical Care Medicine · 2018 · 79 citations · Full text